Bright minds biosciences receives a favorable written opinion from the international searching authority for bmb-202

-- bmb-202 is a highly selective 5-ht2a agonist that exhibits a more than 30-fold selectivity over 5-ht2c and more than 500-fold selectivity over 5-ht2b -- -- bmb-202 is the first clinical candidate from an extensive portfolio of selective 5-ht2a and 5-ht2a/2c agonists inspired from natural compound scaffolds --
DRUG Ratings Summary
DRUG Quant Ranking